Overview

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Status:
RECRUITING

Trial end date:
2028-05-18

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.

Phase:

PHASE3

Details

Lead Sponsor:

Incyte Corporation

Treatments:

ruxolitinib